

Focusing projects with Target Product Profiles (TPPs) and Target Candidate Profiles (TCPs)

Worked Example: ASAP SARS-CoV-2/MERS-CoV Mpro program

Dr Ed Griffen ASAP Lead Optimisation team COVID Moonshot Design Team Leader MedChemica Consultancy Ltd



- What's a TPP and a TCP?
- Why MERS&SARS?

Agenda

- Our approach to TPPs and TCPs ways of working
- What did we learn from SARS2
- MERS&SARS TPP work through
- MERS&SARS TCP work through
- Call for feedback

TPPs and TCPs




- **TPP**:- Target Product Profile
 - properties of the *product* irrespective of biological Mode of Action
 - key part of an investigator's brochure, and in the end the product label

The concept of a target product profile is not special to drug discovery, used across many industries to focus design teams on delivering to the client(patient and clinician) needs

- **TCP:-** Target Candidate Profile
 - what *features of a molecule* are needed to deliver a TPP via a particular Mode of Action
- Many TCPs may deliver to the same TPP
- For examples see

Burrows, et al, New Developments in Anti-Malarial Target Candidate and Product Profiles. Malaria Journal 2017, 16 (1), 26. https://doi.org/10.1186/s12936-016-1675-x.



Why MERS&SARS?: HCoV Summary



	Class		1 st Isolation	Case Fatality Rate
229E	α-CoV	Duvinacovirus	1966	-
OC43	β -CoV lineage A	Embecovirus	1967	-
SARS-CoV	β -CoV lineage B.	Sarbecovirus	2002	9.6%
NL63	α-CoV	Setracovirus	2004	-
HKU1	β -CoV lineage A	Embecovirus	2004	-
MERS-CoV	β -CoV lineage C	Merbecovirus	2012	34.4%
SARS-CoV-2	β -CoV lineage B	Sarbecovirus	2019	3.5%

• Ye at al Int J Biol Sci. 2020 Mar 15;16(10):1686–97.


Anti-MERS-2: Rationale

NON-CONFIDENTIAL



- MERS is endemic in dromedary camels,¹ & climate change is increasing camel population²
- With both SARS-COV2 and MERS endemic in high population LMICs (Egypt, Nigeria, Pakistan total population = 0.5Bn), the opportunity for a recombination event is high and the risk should be mitigated.³
- MERS is an airborne respiratory virus,⁴
- Current MPro inhibitors have MERS as a weak point, other (tested) coronaviridae show broadly equivalent potency with current series,
- A MERS type lineage C β-CoV would not be treatable by existing agents,

high pandemic risk



- (1) Epidemics. 2019 Dec 1;29:100350.
- (2) https://www.bbc.com/future/article/20210122-the-coronavirus-10-times-more-deadly-than-covid


(3) Supplementary recommendations for the epidemiological investigation of SARS-CoV-2 in exposed animals Rome, Italy: FAO; 2021 16 p. https://www.fao.org/documents/card/en/c/cb7141en/

(4) Indoor Air 2018, 28, , 51–63. https://doi.org/10.1111/ina.12430.

Part of ASAP's ethos is to "draft early and refine"

- "good now and improving" beats "perfect in 6 months"
- kaizen continuous improvement
- software dev: agile rather than waterfall development
- "Scout mindset"
 - set an initial goal,
 - start progressing,
 - check if the goal is still appropriate,
 - refine goal, (check if complete!)
 - alter course to head for new goal,

All our TPPs and TCP are "the best we have today, and open for improvement"





NON-CONFIDENTIAL




Another lethal airborne respiratory infection like SARS2:

- goal would be to suppress at epidemic level before becoming pandemic,
- would need to be available orally for health worker treatment / protection & "cordon sanitaire" pre-exposure prophylaxis (PrEP)
- wide range of population would need to be able access therapy
- drug safety consequences
 - access by women of childbearing age
 - no carcinogenicity, mutagenicity, teratogenicity
 - geriatric patients and others with co-morbidities = multiple other therapies,
 - avoid drug-drug interactions: especially CYP P450 inhibitors and transporter inhibitors
 - general highly safe therapies to avoid "pandemic panic hesitancy" issues
 - e.g. Molnupiravir concerns, vaccine fertility misinformation



Assume that for a **direct acting** anti-viral:

 inhibition of viral replication in multiple model cell lines will generate a relevant EC50



- continuous in vivo free drug cover in plasma over the cellular EC50 is a reasonable pharmacodynamic model
 - assuming a relativity well distributed compound where plasma: tissue ratios are reasonable
 - = where the compound can easily access all body compartments and tissues where the virus is replicating
- efficacy in 1 or more animal models of similar disease e.g. MERS as a model for a future hCoV

NON-CONFIDENTIAL



Oral is essential

Property	Minimum Essential	Ideal	for AViDD, iv is imaginable for
Drug Product	oral	iv with oral step down (prophylactic?)	use in ICU, but
Dosing regimen	tid	uid	not a primary goal, iv & oral is
Pre-clinical efficacy	Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model	from a medicinal chemistry perspective very
Transmission blocking	No	Yes	hard as they are conflicting goals (especially in a
Bioavailability / food effect	Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	high dose agent)
Drug-Drug Interactions	No unmanageable risk in terms of solid state or PK interactions	No risks in solid state or PK interactions	
Safety and Tolerability	Few and manageable drug-related SAEs	No drug-related SAEs; minimal drug-related AEs that do not result in Study exclusion	
Pregnancy	Not contra-indicated in second or third trimester	Not contra-indicated in 2nd or 3rd trimester, no embryo-fetal toxicity in 1st trimester in preclinical species	
Shelf life of product	>=2y	>=5y	

TPP – MERS&SARS 000

-RS&SARS2 (June	2022 draft)	NON-CONFIDE	NTIAL OR ACCESSIBLE ACTIVITATE TO Prevent Pendemics
type respiratory beta coronavirus			Animal model
Minimum Essential	<mark>Ideal</mark>		efficacy a reasonable
oral	iv with oral step down (prophylactic?)		surrogate for an
tid	uid		unknown disease, mouse
Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model		most probable at discovery stage, metabolism
Νο	Yes		issues with hamster, logistics with
Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	2	logistics with ferret
No unmanageable risk in terms of solid	No ricks in solid state or DK interactions		

No risks in solid state or PK interactions

that do not result in Study exclusion

No drug-related SAEs; minimal drug-related AEs

Not contra-indicated in 2nd or 3rd trimester, no

embryo-fetal toxicity in 1st trimester in preclinical

Shelf life of product >=2v

Name: TPP-1: MERS type respiratory beta

trimester

Property

Drug Product

Transmission

Bioavailability /

blocking

food effect

Drug-Drug

Safety and

Tolerability

Pregnancy

Interactions

Dosing regimen

Pre-clinical efficacy

state or PK interactions

Few and manageable drug-related SAEs

Not contra-indicated in second or third

>=5y

species

NON-CONFIDENTIAL



Property	Minimum Essential	<mark>Ideal</mark>	
Drug Product	oral	iv with oral step down (prophylactic?)	
Dosing regimen	tid	uid	
Pre-clinical efficacy	Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model	A low bioavailability if not variable
Transmission blocking	No	Yes	would be possible - but
Bioavailability / food effect	Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	and extremely potent agent.
Drug-Drug Interactions	No unmanageable risk in terms of solid state or PK interactions	No risks in solid state or PK interactions	Fed/fasted is a compliance issue
Safety and Tolerability	Few and manageable drug-related SAEs	No drug-related SAEs; minimal drug-related AEs that do not result in Study exclusion	
Pregnancy	Not contra-indicated in second or third trimester	Not contra-indicated in 2nd or 3rd trimester, no embryo-fetal toxicity in 1st trimester in preclinical species	
Shelf life of product	>=2y	>=5y	





Property	Minimum Essential	ldeal	
Drug Product	oral	iv with oral step down (prophylactic?)	
Dosing regimen	tid	uid	
Pre-clinical efficacy	Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model	PK interactions - is critical with patients on multiple
Transmission blocking	No	Yes	therapies, CYP P450 inhibitors could cause
Bioavailability / food effect	Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	overdosing of other
Drug-Drug Interactions	No unmanageable risk in terms of solid state or PK interactions	No risks in solid state or PK interactions	therapeutics with the potential for
Safety and Tolerability	Few and manageable drug-related SAEs	No drug-related SAEs; minimal drug-related AEs that do not result in Study exclusion	lethal interactions.
Pregnancy	Not contra-indicated in second or third trimester	Not contra-indicated in 2nd or 3rd trimester, no embryo-fetal toxicity in 1st trimester in preclinical species	
Shelf life of product	>=2y	>=5y	





Property	Minimum Essential	<mark>ldeal</mark>	
Drug Product	oral	iv with oral step down (prophylactic?)	Serious Adverse
Dosing regimen	tid	uid	events in a new
Pre-clinical efficacy	Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model	therapeutic would, from the COVID-19 experience,
Transmission blocking	No	Yes	have the potential to critically impede
Bioavailability / food effect	Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	both clinical trials and effective use.
Drug-Drug Interactions	No unmanageable risk in terms of solid state or PK interactions	No risks in solid state or PK interactions	
Safety and Tolerability	Few and manageable drug-related SAEs	No drug-related SAEs; minimal drug-related AEs that do not result in Study exclusion	~
Pregnancy	Not contra-indicated in second or third trimester	Not contra-indicated in 2nd or 3rd trimester, no embryo-fetal toxicity in 1st trimester in preclinical species	
Shelf life of product	>=2y	>=5y	

NON-CONFIDENTIAL

ITIAL CAREAR AND ACCESSIBLE ANTIVITALS TO Prevent Pandemics

Property	Minimum Essential	<mark>ldeal</mark>	COVID-19 has demonstrated
Drug Product	oral	iv with oral step down (prophylactic?)	that potential
Dosing regimen	tid	uid	contraindication in pregnancy is
Pre-clinical efficacy	Efficacy in >= 3 relevant cell models with projected (including primary cell model) 24h cover over EC90 from TID dosing	3 log drop in viral load in mouse model	an issue of uptake in HMIC's and as effective
Transmission blocking	No	Yes	contraception is unavailable in many LMICs
Bioavailability / food effect	Predicted >= 30% / fed fasted <3x change	Predicted >= 50% / fed fasted no change	contraindication in pregnancy
Drug-Drug Interactions	No unmanageable risk in terms of solid state or PK interactions	No risks in solid state or PK interactions	becomes contraindication for all women of
Safety and Tolerability	Few and manageable drug-related SAEs	No drug-related SAEs; minimal drug-related AEs that do not result in Study exclusion	child bearing age - a critical failure.
Pregnancy	Not contra-indicated in second or third trimester	Not contra-indicated in 2nd or 3rd trimester, no embryo-fetal toxicity in 1st trimester in preclinical species	
Shelf life of product	>=2y	>=5y	

NON-CONFIDENTIAL



Property		Target range – Minimal	ldeal	Enzyme target is
MERS protease	IС ₅₀	< 20 nM	<10nM	dependant on the
SARS2 protease	IC ₅₀	< 20 nM	<10nM	enzyme→ cell dropoff - unclear until we have
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		enough compounds with a range of potencies - but
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral load in mouse model	assume 10x dropoff initially and refine
PK-PD Cmin > EC90 (CPE	E) for 24h	projected human dosed TID	UID	
Coronavirus spectrum		MERS with SARS2	additional CoV	
Route of administration & free	quency	Oral, no 'PK enhancers' TID	Oral UID	
solubility		>=100µM,		
half-life		>= 8 h (human) est from rat	>= 12h	
safety		No significant human protease activity >50% at 10µM (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP)		
		hERG and NaV1.5 IC ₅₀ > 50 μM No significant change in QTc No mutagenicity or teratogenicity risk		

NON-CONFIDENTIAL



NON-CONFIDENTIAL



MERS protease	IC ₅₀	< 20 nM	<10pM	
			<10nM	
SARS2 protease	IC 50	< 20 nM	<10nM	
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral load in mouse model	Very much a work in
PK-PD Cmin > EC90 (CPE) for 24h	projected human dosed TID	UID	 significant reduction measured animal vir
Coronavirus spectrum		MERS with SARS2	additional CoV	seems a minimal rec
Route of administration & frequency		Oral, no 'PK enhancers' TID	Oral UID	
solubility		>=100µM,		
half-life		>= 8 h (human) est from rat	>= 12h	
safety		No significant human protease activity >50% at 10µM (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP)		
		hERG and NaV1.5 IC ₅₀ > 50 μM No significant change in QTc No mutagenicity or teratogenicity risk		

NON-CONFIDENTIAL



roperty		Target range – Minimal	Ideal
ERS protease	IC ₅₀	< 20 nM	<10nM
ARS2 protease	IC ₅₀	< 20 nM	<10nM
ral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2	
nimal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral load in mouse model
K-PD Cmin > EC90 (CPE)) for 24h	projected human dosed TID	UID
pronavirus spectrum		MERS with SARS2	additional CoV
oute of administration & freq	uency	Oral, no 'PK enhancers' TID	Oral UID
blubility		>=100µM,	
alf-life		>= 8 h (human) est from rat	>= 12h
afety		No significant human protease activity >50% at 10 μ M (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP) hERG and NaV1.5 IC ₅₀ > 50 μ M No significant change in QTc No mutagenicity or teratogenicity risk	

NON-CONFIDENTIAL



Property		Target range – Minimal	Ideal	
MERS protease	IС ₅₀	< 20 nM	<10nM	
SARS2 protease	IC ₅₀	< 20 nM	<10nM	
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral load in mouse model	
PK-PD Cmin > EC90 (CPE	E) for 24h	projected human dosed TID	UID	
Coronavirus spectrum		MERS with SARS2	additional CoV	
Route of administration & free	quency	Oral, no 'PK enhancers' TID	Oral UID	PK enhancers such as
solubility		>=100µM,		Ritonavir generate DDI's large numbers of other C
half-life		>= 8 h (human) est from rat	>= 12h	P450 metabolised drugs
safety		No significant human protease activity >50% at 10 μ M (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP) hERG and NaV1.5 IC ₅₀ > 50 μ M No significant change in QTc No mutagenicity or teratogenicity risk		

NON-CONFIDENTIAL



NON-CONFIDENTIAL



Property		Target range – Minimal	ldeal	Protease panel is the target
MERS protease	IC ₅₀	< 20 nM	<10nM	specific risk factor, non-selective protease
SARS2 protease	IC ₅₀	< 20 nM	<10nM	inhibitors will generate toxicities that will probably be
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		unacceptable, flag for early inclusion in the test cascade
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral load in mouse model	
PK-PD Cmin > EC90 (CPE)	for 24h	projected human dosed TID	UID	
Coronavirus spectrum		MERS with SARS2	additional CoV	
Route of administration & frequ	lency	Oral, no 'PK enhancers' TID	Oral UID	
solubility		>=100µM,		
half-life		>= 8 h (human) est from rat	>= 12h	
safety		No significant human protease activity >50% at 10 μ M (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP) hERG and NaV1.5 IC ₅₀ > 50 μ M No significant change in QTc No mutagenicity or teratogenicity risk		

NON-CONFIDENTIAL



Property		Target range – Minimal	Ideal	Protease panel is the target
MERS protease	IC ₅₀	< 20 nM	<10nM	specific risk factor, non-selective protease
SARS2 protease	IC ₅₀	< 20 nM	<10nM	inhibitors will generate toxicities that will probably be
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		unacceptable, flag for early inclusion in the test cascade
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral loa in mouse model	ad
PK-PD Cmin > EC90 (CPE)	.) for 24h	projected human dosed TID	UID	
Coronavirus spectrum		MERS with SARS2	additional CoV	
Route of administration & freq	Juency	Oral, no 'PK enhancers' TID	Oral UID	
solubility		>=100µM,		CYPs and transporters - DDI critical
half-life		>= 8 h (human) est from rat	>= 12h	Critical
safety		No significant human protease activity >50% at 10 μ M (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP) hERG and NaV1.5 IC ₅₀ > 50 μ M No significant change in QTc No mutagenicity or teratogenicity risk		

NON-CONFIDENTIAL



Property		Target range – Minimal	Ideal	Protease panel is the target
MERS protease	IC ₅₀	< 20 nM	<10nM	specific risk factor, non-selective protease
SARS2 protease	IC ₅₀	< 20 nM	<10nM	inhibitors will generate toxicities that will probably be
viral replication CPE assay	EC ₅₀	=< 100nM MERS +SARS2		unacceptable, flag for early inclusion in the test cascade
Animal model efficacy		Efficacy in >= 3 relevant cell models with projected 24h cover over EC90 from TID dosing	>=0.6 log drop in viral loac in mouse model	d
PK-PD Cmin > EC90 (CPE)	.) for 24h	projected human dosed TID	UID	
Coronavirus spectrum		MERS with SARS2	additional CoV	
Route of administration & freq	Juency	Oral, no 'PK enhancers' TID	Oral UID	
solubility		>=100µM,		CYPs and transporters - DDI
half-life		>= 8 h (human) est from rat	>= 12h	critical
safety		No significant human protease activity >50% at 10 μ M (Nanosyn 61 protease panel) Only reversible and monitorable toxicities (NOAEL > 30x Cmax) No significant DDI - clean in 5 CYP450 isoforms No critical transporter inhibition (<i>e.g.</i> OATP) hERG and NaV1.5 IC ₅₀ > 50 μ M No significant change in QTc No mutagenicity or teratogenicity risk		Ames test as 1st test for mutagenicity/ teratogenicity

ASAP: Lead Optimization

SARS-CoV-2 / MERS-CoV - Assay Cascade - re-model with series development

NON-CONFIDENTIAL



Area	Assays	Entry Criteria	
In Vitro biochemistry	SARS2 Mpro, MERS Mpro	All compounds	Design, Docking, FEP
Cellular assay	SARS2 , MERS	SARS2&MERS MPro IC50 <1uM	Synthesis
In vitro ADMET Tier 1	solubility(kinetic), LogD, mics(hu), <mark>mics(mouse)</mark> MDCK Permeability , A—>B	SARS2&MERS MPro IC50 <1uM	SARS2 MARS
In vitro ADMET Tier 2	Thermodynamic Solubility, MDCK-MDR1 ER microsome(rat), hepatocyte (mouse, rat, human) Plasma Protein binding (mouse, rat, human, FCS) CYP Inhibition 5 Cyps, Patch clamp hERG, NaV 1.5, CaV 1.2	critical leads (eg for RLM: heps: bioavailability comparison) + in vivo efficacy candidates	SARS2 Mpro, MERS Mpro Tier 1 in vitro SARS2 & MERS
In vitro ADMET Tier 3	3A4 TDI, PXR induction, BSEP, AMES (2 Strains) Dog: Microsome, Hepatocyte, Plasma Protein – Dog	critical leads + short list	ADMET Cellular anti-viral
In vivo ADMET Tier 1	mouse iv cassette 5 compounds per cassette	critical leads + rodent mics Clint < 100ml/min/mg & cellular efficacy IC50 < 1uM	Tier 1 in vivo ADMET
In vivo ADMET Tier 2	Formulation studies, <mark>Mouse iv, po bioavailability,</mark> Rat iv, po & bioavailability,	in vivo efficacy candidates	Tier 2 in vitro ADMET
Efficacy studies	Mouse SARS2 and Mouse MERS	expectation of free cover over EC50 for 24h	Efficacy Studies Tier 3 in vitro ADMET
Selectivity / tox screening	Protease panel (61) CEREP in vitro tox panel	critical leads + short list	(mouse)

Project 5 : Lead Optimization SARS-CoV-2 / MERS-CoV MPro - MERS vs SARS2 background



Structure				HN H O HN H O H H H H H H H H H H H H H H H H H H	
Identifier	Nirmatrelvir	Carlsson-19 /	VLA-UCB-29506327-1	Groutas-3c	MIK-ENA-17e27e9c-1
SARS2 MPro IC50/nM	3	10	1320	260	10
MERS MPro IC50/nM	187	245	32000	130	2360
MERS/SARS2 enzyme IC50 ratio	62	25	24	0.5	236
other data		low solubility		poor Cathepsin L selectivity	
MERS CPE assay Vero E6 EC50 / uM	4.4	17.5		MERS cellular data not reported	5.3
Comment	covalent	literature MERS cell data: CPE Huh7EC50: : 200nM	Wuxi MERS enzyme data - repeat @ Weizmann	covalent, literature data only	SARS2 Mpro analogue structure not covalent

Carlsson et al: J. Am. Chem. Soc. 2022, 144 (7), 2905 Groutas et al: : J. Med. Chem. 2022, 65, 7818–7832 Enzyme: cell dropoff may be dependent on covalent/non covalent mode, or series permeability - much more data needed.

- We're interested in how other people define their TPPs and TCPs
- Particularly interested where other groups are working on MERS +/- other huCoV
 - how are you considering efficacy
 - what are your safety criteria?
 - how are you translating those into your test cascades

NON-CONFIDENTIAL

- 1. Have you considered time to steady state as a metric?
 - a. we're more concerned with time to free Cmin/ED90 -fast to steady state is usually associated with highly cleared compounds, that would give a high peak-trough swing which might be more of a risk for in vivo toxicity
- 2. Why use bioavailability as the metric rather than dose?
 - a. we should use both but we'd tolerate a dose as high as is practically useful (3g/day?) whereas low bioavailability could lead to variability and thence variability in outcomes
- 3. What about having lung exposure compared to lung in the cascade?
 - a. currently we'd thought of having it as a problem solving experiment of we have unexpected lack of efficacy in animal models as it's an expensive experiment to do, but we could do it in parallel with animal efficacy
- 4. Big debate question: is in vivo efficacy essential for pandemic preparedness compared to efficacy in multiple cell models of a wide range of viruses and good predicted human pharmacokinetics
 - a. the argument against mouse efficacy is that mice metabolise compounds easily, against that is the NIH and clinician interest in seeing in vivo efficacy in an animal model for progression as a risk reduction for taking into Phase 1. This remains a live argument.